Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 171

1.

Everolimus-eluting Bioresorbable Scaffolds in Patients with Coronary Artery Disease: Results from the German-Austrian ABSORB RegIstRy (GABI-R).

Nef HM, Wiebe J, Kastner J, Mehilli J, Münzel T, Naber C, Neumann T, Richardt G, Schmermund A, Wöhrle J, Zahn R, Riemer T, Achenbach S, Hamm CW.

EuroIntervention. 2017 Aug 22. pii: EIJ-D-17-00330. doi: 10.4244/EIJ-D-17-00330. [Epub ahead of print]

2.

Clinical Restenosis and its Predictors after Implantation of Everolimus-Eluting Bioresorbable Vascular Scaffolds: Results from the GABI-R Registry.

Mehilli J, Achenbach S, Woehrle J, Baquet M, Riemer T, Muenzel T, Nef H, Naber C, Richardt G, Zahn R, Gori T, Neumann T, Kastner J, Schmermund A, Hamm C.

EuroIntervention. 2017 Jun 27. pii: EIJ-D-17-00291. doi: 10.4244/EIJ-D-17-00291. [Epub ahead of print]

3.

12 months outcomes after Bioresorbable Vascular Scaffold implantation in Patients with Acute Coronary Syndromes. Data from the European Multicentre GHOST-EU Extended Registry.

Schnorbus B, Wiebe J, Capodanno D, Brugaletta S, Geraci S, Mehilli J, Latib A, Lesiak M, Jensen C, Mattesini A, Münzel T, Capranzano P, Di Mario C, Naber C, Araszkiewicz A, Colombo A, Caramanno G, Sabate M, Tamburino C, Nef H, Gori T.

EuroIntervention. 2017 Mar 21. pii: EIJ-D-16-00568. doi: 10.4244/EIJ-D-16-00568. [Epub ahead of print]

4.

Bioresorbable Everolimus-Eluting Vascular Scaffold for Long Coronary Lesions: A Subanalysis of the International, Multicenter GHOST-EU Registry.

Geraci S, Kawamoto H, Caramanno G, Ruparelia N, Capodanno D, Brugaletta S, Gori T, Nef H, Sabate M, Mehilli J, Lesiak M, Naber C, Di Mario C, Capranzano P, Wiebe J, Araszkiewicz A, Pyxaras S, Mattesini A, Münzel T, Tamburino C, Colombo A, Latib A.

JACC Cardiovasc Interv. 2017 Mar 27;10(6):560-568. doi: 10.1016/j.jcin.2016.12.013. Epub 2017 Mar 1.

PMID:
28259663
5.

Predilation, sizing and post-dilation scoring in patients undergoing everolimus-eluting bioresorbable scaffold implantation for prediction of cardiac adverse events: development and internal validation of the PSP score.

Ortega-Paz L, Capodanno D, Gori T, Nef H, Latib A, Caramanno G, Di Mario C, Naber C, Lesiak M, Capranzano P, Wiebe J, Mehilli J, Araszkiewicz A, Pyxaras S, Mattesini A, Geraci S, Naganuma T, Colombo A, Münzel T, Sabaté M, Tamburino C, Brugaletta S.

EuroIntervention. 2017 Apr 20;12(17):2110-2117. doi: 10.4244/EIJ-D-16-00974.

PMID:
28246060
6.

A multicentre European registry to evaluate the Direct Flow Medical transcatheter aortic valve system for the treatment of patients with severe aortic stenosis.

Naber CK, Pyxaras SA, Ince H, Frambach P, Colombo A, Butter C, Gatto F, Hink U, Nickenig G, Bruschi G, Brueren G, Tchétché D, Den Heijer P, Schillinger W, Scholtz S, Van der Heyden J, Lefèvre T, Gilard M, Kuck KH, Schofer J, Divchev D, Baumgartner H, Asch F, Wagner D, Latib A, De Marco F, Kische S.

EuroIntervention. 2016 Dec 10;12(11):e1413-e1419. doi: 10.4244/EIJ-D-15-00511.

7.

Computing Methods for Composite Clinical Endpoints in Unprotected Left Main Coronary Artery Revascularization: A Post Hoc Analysis of the DELTA Registry.

Capodanno D, Gargiulo G, Buccheri S, Chieffo A, Meliga E, Latib A, Park SJ, Onuma Y, Capranzano P, Valgimigli M, Narbute I, Makkar RR, Palacios IF, Kim YH, Buszman PE, Chakravarty T, Sheiban I, Mehran R, Naber C, Margey R, Agnihotri A, Marra S, Leon MB, Moses JW, Fajadet J, Lefèvre T, Morice MC, Erglis A, Alfieri O, Serruys PW, Colombo A, Tamburino C; DELTA Investigators.

JACC Cardiovasc Interv. 2016 Nov 28;9(22):2280-2288. doi: 10.1016/j.jcin.2016.08.025.

PMID:
27884354
8.

2-Year Outcomes of High Bleeding Risk Patients After Polymer-Free Drug-Coated Stents.

Garot P, Morice MC, Tresukosol D, Pocock SJ, Meredith IT, Abizaid A, Carrié D, Naber C, Iñiguez A, Talwar S, Menown IBA, Christiansen EH, Gregson J, Copt S, Hovasse T, Lurz P, Maillard L, Krackhardt F, Ong P, Byrne J, Redwood S, Windhövel U, Greene S, Stoll HP, Urban P; LEADERS FREE Investigators.

J Am Coll Cardiol. 2017 Jan 17;69(2):162-171. doi: 10.1016/j.jacc.2016.10.009. Epub 2016 Oct 30.

9.

Impact of overlapping on 1-year clinical outcomes in patients undergoing everolimus-eluting bioresorbable scaffolds implantation in routine clinical practice: Insights from the European multicenter GHOST-EU registry.

Ortega-Paz L, Capodanno D, Giacchi G, Gori T, Nef H, Latib A, Caramanno G, Di Mario C, Naber C, Lesiak M, Capranzano P, Wiebe J, Mehilli J, Araszkiewicz A, Pyxaras S, Mattesini A, Geraci S, Naganuma T, Colombo A, Münzel T, Sabaté M, Tamburino C, Brugaletta S.

Catheter Cardiovasc Interv. 2017 Apr;89(5):812-818. doi: 10.1002/ccd.26674. Epub 2016 Aug 12.

PMID:
27515568
10.

Long-term clinical outcomes after percutaneous coronary intervention versus coronary artery bypass grafting for acute coronary syndrome from the DELTA registry: a multicentre registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment.

Pyxaras SA, Hunziker L, Chieffo A, Meliga E, Latib A, Park SJ, Onuma Y, Capranzano P, Valgimigli M, Narbute I, Makkar RR, Palacios IF, Kim YH, Buszman PP, Chakravarty T, Sheiban I, Mehran R, Margey R, Agnihotri A, Marra S, Capodanno D, Leon MB, Moses JW, Fajadet J, Lefevre T, Morice MC, Erglis A, Tamburino C, Alfieri O, Serruys PW, Colombo A, Naber CK.

EuroIntervention. 2016 Aug 5;12(5):e623-31. doi: 10.4244/EIJV12I5A102.

11.

Acute and 30-Day Outcomes in Women After TAVR: Results From the WIN-TAVI (Women's INternational Transcatheter Aortic Valve Implantation) Real-World Registry.

Chieffo A, Petronio AS, Mehilli J, Chandrasekhar J, Sartori S, Lefèvre T, Presbitero P, Capranzano P, Tchetche D, Iadanza A, Sardella G, Van Mieghem NM, Meliga E, Dumonteil N, Fraccaro C, Trabattoni D, Mikhail GW, Sharma S, Ferrer MC, Naber C, Kievit P, Faggioni M, Snyder C, Morice MC, Mehran R; WIN-TAVI Investigators.

JACC Cardiovasc Interv. 2016 Aug 8;9(15):1589-600. doi: 10.1016/j.jcin.2016.05.015.

12.

Bioresorbable vascular scaffold use for coronary bifurcation lesions: A substudy from GHOST EU registry.

Naganuma T, Colombo A, Lesiak M, Capodanno D, Gori T, Nef H, Caramanno G, Naber C, Di Mario C, Ruparelia N, Capranzano P, Wiebe J, Araszkiewicz A, Geraci S, Kawamoto H, Pyxaras S, Mattesini A, Münzel T, Tamburino C, Latib A.

Catheter Cardiovasc Interv. 2017 Jan;89(1):47-56. doi: 10.1002/ccd.26634. Epub 2016 Jul 14.

PMID:
27414021
13.

Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a Leaders Free ACS sub-study.

Naber CK, Urban P, Ong PJ, Valdes-Chavarri M, Abizaid AA, Pocock SJ, Fabbiocchi F, Dubois C, Copt S, Greene S, Morice MC; LEADERS FREE Investigators.

Eur Heart J. 2017 Apr 1;38(13):961-969. doi: 10.1093/eurheartj/ehw203.

PMID:
27190095
14.

Validated Risk Score for Predicting 6-Month Mortality in Infective Endocarditis.

Park LP, Chu VH, Peterson G, Skoutelis A, Lejko-Zupa T, Bouza E, Tattevin P, Habib G, Tan R, Gonzalez J, Altclas J, Edathodu J, Fortes CQ, Siciliano RF, Pachirat O, Kanj S, Wang A; International Collaboration on Endocarditis (ICE) Investigators.

J Am Heart Assoc. 2016 Apr 18;5(4):e003016. doi: 10.1161/JAHA.115.003016.

15.

Transapical valve-in-valve TAVI in a patient with two failing surgical bioprostheses with Edwards SAPIEN 3 valves using a cerebral protection system.

Wolf A, Schmitz T, Bigdeli H, Naber CK.

EuroIntervention. 2016 Mar;11(12):1432. doi: 10.4244/EIJV11I12A274. No abstract available.

16.

1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries.

Tamburino C, Capranzano P, Gori T, Latib A, Lesiak M, Nef H, Caramanno G, Naber C, Mehilli J, Di Mario C, Sabaté M, Münzel T, Colombo A, Araszkiewicz A, Wiebe J, Geraci S, Jensen C, Mattesini A, Brugaletta S, Capodanno D.

JACC Cardiovasc Interv. 2016 Mar 14;9(5):440-9. doi: 10.1016/j.jcin.2015.10.042. Epub 2016 Jan 6.

17.

Real-world multicentre experience with the Direct Flow Medical repositionable and retrievable transcatheter aortic valve implantation system for the treatment of high-risk patients with severe aortic stenosis.

Naber CK, Pyxaras SA, Ince H, Latib A, Frambach P, den Heijer P, Wagner D, Butter C, Colombo A, Kische S.

EuroIntervention. 2016 Feb;11(11):e1314-20. doi: 10.4244/EIJV11I11A254.

18.

Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk.

Urban P, Meredith IT, Abizaid A, Pocock SJ, Carrié D, Naber C, Lipiecki J, Richardt G, Iñiguez A, Brunel P, Valdes-Chavarri M, Garot P, Talwar S, Berland J, Abdellaoui M, Eberli F, Oldroyd K, Zambahari R, Gregson J, Greene S, Stoll HP, Morice MC; LEADERS FREE Investigators.

N Engl J Med. 2015 Nov 19;373(21):2038-47. doi: 10.1056/NEJMoa1503943. Epub 2015 Oct 14.

19.

Evaluation of the short- and long-term safety and therapy outcomes of the everolimus-eluting bioresorbable vascular scaffold system in patients with coronary artery stenosis: Rationale and design of the German-Austrian ABSORB RegIstRy (GABI-R).

Nef H, Wiebe J, Achenbach S, Münzel T, Naber C, Richardt G, Mehilli J, Wöhrle J, Neumann T, Biermann J, Zahn R, Kastner J, Schmermund A, Pfannebecker T, Schneider S, Limbourg T, Hamm CW.

Cardiovasc Revasc Med. 2016 Jan-Feb;17(1):34-7. doi: 10.1016/j.carrev.2015.09.002. Epub 2015 Sep 10.

PMID:
26431767
20.

Early and midterm outcomes of bioresorbable vascular scaffolds for ostial coronary lesions: insights from the GHOST-EU registry.

Gori T, Wiebe J, Capodanno D, Latib A, Lesiak M, Pyxaras SA, Mehilli J, Caramanno G, Di Mario C, Brugaletta S, Weber J, Capranzano P, Sabate M, Mattesini A, Geraci S, Naber CK, Araszkiewicz A, Colombo A, Tamburino C, Nef H, Münzel T.

EuroIntervention. 2016 Aug 5;12(5):e550-6. doi: 10.4244/EIJY15M09_10.

Supplemental Content

Loading ...
Support Center